Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of TAK-925 as a Potent, Selective, and Brain-Penetrant Orexin 2 Receptor Agonist
Tatsuhiko Fujimoto, Kentaro Rikimaru, Koichiro Fukuda, et al.
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 3, pp. 457-462
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Effects of the orexin receptor 2 agonist danavorexton on emergence from general anaesthesia and opioid-induced sedation, respiratory depression, and analgesia in rats and monkeys
Motohisa Suzuki, Eri Shiraishi, James J. Cronican, et al.
British Journal of Anaesthesia (2024) Vol. 132, Iss. 3, pp. 541-552
Open Access | Times Cited: 8
Orexin 2 receptor‐selective agonist danavorexton ( TAK ‐925) promotes wakefulness in non‐human primates and healthy individuals
Rebecca Evans, Haruhide Kimura, Masato Nakashima, et al.
Journal of Sleep Research (2023) Vol. 32, Iss. 5
Open Access | Times Cited: 19
From past to future: 50 years of pharmacological interventions to treat narcolepsy
Éric Konofal
Pharmacology Biochemistry and Behavior (2024) Vol. 241, pp. 173804-173804
Open Access | Times Cited: 6
Molecular mechanism of the wake-promoting agent TAK-925
Jie Yin, Yanyong Kang, Aaron P. McGrath, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 24
Narcolepsy: a model interaction between immune system, nervous system, and sleep-wake regulation
Daniela Latorre, Federica Sallusto, Claudio L. Bassetti, et al.
Seminars in Immunopathology (2022) Vol. 44, Iss. 5, pp. 611-623
Open Access | Times Cited: 23
TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy
Takashi Ishikawa, Hiroe Hara, Ayumi Kawano, et al.
Journal of Pharmacology and Experimental Therapeutics (2023) Vol. 385, Iss. 3, pp. 193-204
Open Access | Times Cited: 15
Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders
Alessandro Bonifazi, Fabio Del Bello, Gianfabio Giorgioni, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 5, pp. 1607-1667
Closed Access | Times Cited: 13
Design and Synthesis of Orexin 1 Receptor-Selective Agonists
Keita Iio, Kao Hashimoto, Yasuyuki Nagumo, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 8, pp. 5453-5464
Open Access | Times Cited: 13
The present and future of synthetic orexin receptor agonists
Tsuyoshi Saitoh, Takeshi Sakurai
Peptides (2023) Vol. 167, pp. 171051-171051
Open Access | Times Cited: 13
Orexin receptor 2 agonist activates diaphragm and genioglossus muscle through stimulating inspiratory neurons in the pre-Bötzinger complex, and phrenic and hypoglossal motoneurons in rodents
Ryuji Yamada, Tatsuki Koike, Masanori Nakakariya, et al.
PLoS ONE (2024) Vol. 19, Iss. 6, pp. e0306099-e0306099
Open Access | Times Cited: 4
The Orexin receptors: Structural and anti-tumoral properties
Alain Couvineau, Pascal Nicole, Valérie Gratio, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 20
Safety and pharmacodynamics of a single infusion of danavorexton in adults with idiopathic hypersomnia
Emmanuel Mignot, Richard Bogan, Hélène A. Emsellem, et al.
SLEEP (2023) Vol. 46, Iss. 9
Open Access | Times Cited: 11
Danavorexton, a selective orexin 2 receptor agonist, provides a symptomatic improvement in a narcolepsy mouse model
Takashi Ishikawa, Hiroe Hara, Ayumi Kawano, et al.
Pharmacology Biochemistry and Behavior (2022) Vol. 220, pp. 173464-173464
Open Access | Times Cited: 17
Novel orexin receptor agonists based on arene- or pyridine-fused 1,3-dihydro-2H-imidazole-2-imines
Wentian Wang, Alok Ranjan, Wei Zhang, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 99, pp. 129624-129624
Open Access | Times Cited: 3
Current development in sulfonamide derivatives to enable CNS-drug discovery
Klaudia Blicharz-Futera, Michał Kamiński, Katarzyna Grychowska, et al.
Bioorganic Chemistry (2024) Vol. 156, pp. 108076-108076
Closed Access | Times Cited: 2
The distribution of hypocretin/orexin receptor mRNA in the mouse and human brain
Sanjida Mir, Ryan J. Keenan, Romke Bron, et al.
Medicine in Drug Discovery (2024) Vol. 24, pp. 100202-100202
Open Access | Times Cited: 1
Computational Analysis of Fully Activated Orexin Receptor 2 Across Various Thermodynamic Ensembles with Surface Tension Monitoring
Rafael Doležal
(2024)
Open Access | Times Cited: 1
Precocious puberty in narcolepsy type 1: Orexin loss and/or neuroinflammation, which is to blame?
Silvia Melzi, Vincent Prévot, Christelle Peyron
Sleep Medicine Reviews (2022) Vol. 65, pp. 101683-101683
Open Access | Times Cited: 7
Design and synthesis of novel orexin 2 receptor agonists with a 1,3,5‑trioxazatriquinane skeleton
Mao Amezawa, Naoshi Yamamoto, Yasuyuki Nagumo, et al.
Bioorganic & Medicinal Chemistry Letters (2023) Vol. 82, pp. 129151-129151
Closed Access | Times Cited: 3
In Silico Positional Analogue Scanning with Amber GPU-TI
Yuan Hu, Ingo Muegge
Journal of Chemical Information and Modeling (2022) Vol. 62, Iss. 18, pp. 4448-4459
Closed Access | Times Cited: 4
What evidence is there for implicating the brain orexin system in neuropsychiatric symptoms in dementia?
Giorgio Bergamini, Preciosa Coloma, Helene Massinet, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 4
Harnessing conformational drivers in drug design
Praful Chovatia, A. Pia Sanzone, Gert-Jan Hofman, et al.
Progress in medicinal chemistry (2024), pp. 1-60
Closed Access
Narcolepsy and Orexin Receptor 2
Haruhide Kimura
(2024), pp. 1-22
Closed Access
Synthesis of Orexin 2 Receptor Agonist TAK-925
Philip Kocienski
Synfacts (2022) Vol. 18, Iss. 06, pp. 0593-0593
Closed Access
Aktuelle Entwicklungen in der Schlafforschung und Schlafmedizin – eine Einschätzung der AG „Narkolepsie, Hypersomnie und Hypersomnolenz“
Christian Veauthier, Ulf Kallweit, Peter Geisler, et al.
Somnologie - Schlafforschung und Schlafmedizin (2022) Vol. 26, Iss. 3, pp. 167-168
Closed Access
Page 1 - Next Page

Scroll to top